Human Pathology
Volume 41, Issue 9 , Pages 1210-1219 , September 2010

S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy

  • Mary Levy, DO

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • ,
  • Fan Lin, MD, PhD

      Affiliations

    • Department of Laboratory Medicine, Geisinger Medical Center, Danville, PA 17821, USA
    • ,
  • Haodong Xu, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    • ,
  • Deepti Dhall, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • ,
  • Betsy O. Spaulding, BS

      Affiliations

    • Dako North America, Carpinteria, CA 93013, USA
    • ,
  • Hanlin L. Wang, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    • Corresponding Author InformationCorresponding author.

Received 12 December 2009 ,Revised 21 January 2010 ,Accepted 22 January 2010.

References 

  1. Allen PJ, Reiner AS, Gonen M, et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB Surg. 2008;10:341–346
  2. Carpelan-Holmström M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385–387
  3. Fitzgerald TL, Hickner ZJ, Schmitz M, et al. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas. 2008;37:134–138
  4. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB Surg. 2008;10:77–82
  5. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  6. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579
  7. Tan G, Yilmaz A, De Young BR, et al. Immunohistochemical analysis of biliary tract lesions. Appl Immunohistochem Mol Morphol. 2004;12:193–197
  8. Karamitopoulou E, Tornillo L, Zlobec I, et al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol. 2008;130:780–786
  9. Agrawal S, Kuvshinoff BW, Khoury T, et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007;11:445–451
  10. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862–3868
  11. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838–845
  12. Javle MM, Tan D, Yu J, et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004;51:1653–1657
  13. Obama K, Ura K, Li M, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339–1348
  14. Su MC, Hsu C, Kao HL, et al. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 2006;235:34–39
  15. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357–366
  16. Tascilar M, Offerhaus GJ, Altink R, et al. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol. 2001;116:831–837
  17. Zhao H, Davydova L, Mandich D, et al. S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol. 2007;127:374–379
  18. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78–91
  19. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn. 2008;8:557–558
  20. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008;52:133–138
  21. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188–195
  22. Zhao H, Mandich D, Cartun RW, et al. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007;35:700–704
  23. Ligato S, Zhao H, Mandich D, et al. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies. Diagn Cytopathol. 2008;36:561–567
  24. Pryor JG, Bourne PA, Yang Q, et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431–437
  25. Becker T, Gerke V, Kube E, et al. S100P, a novel Ca(2+)-binding protein from human placenta: cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207:541–547
  26. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637–668
  27. Parkkila S, Pan PW, Ward A, et al. The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol. 2008;8:2
  28. Deng H, Shi J, Wilkerson M, et al. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129:81–88
  29. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81–92
  30. Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 2006;12:5411–5416
  31. Whiteman HJ, Weeks ME, Dowen SE, et al. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res. 2007;67:8633–8642
  32. Sato N, Fukushima N, Matsubayashi H, et al. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23:1531–1538
  33. Clark PE, Cookson MS. The von Hippel-Lindau gene: turning discovery into therapy. Cancer. 2008;113(Suppl):1768–1778
  34. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA. 1998;95:11661–11666
  35. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145–173
  36. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129:592–605

 Presented in an abstract form at the 97th annual meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 7-13, 2009.

PII: S0046-8177(10)00054-7

doi: 10.1016/j.humpath.2010.01.014

Human Pathology
Volume 41, Issue 9 , Pages 1210-1219 , September 2010

Article Tools

* Image Usage & Resolution